Denis, Chloé ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
Sakalihasan, Sarah ; Université de Liège - ULiège > Master méd. (180 crédits)
FRERES, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
WITHOFS, Nadia ; Centre Hospitalier Universitaire de Liège - CHU > Département de Physique Médicale > Service médical de médecine nucléaire et imagerie onco
SAUTOIS, Brieuc ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
Language :
English
Title :
Cemiplimab for cisplatin resistant metastatic penile cancer
Zhang S, Zhu Y, Ye D. Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. Oncotarget. 2015; 6(31): 32212-9.
Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamouscell carcinoma of the head and neck. N Engl J Med. 2016; 375(19): 1856-67.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212): 1915-28.
Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020; 21(2): 294-305.
Hakenberg OW, Minhas ES, Necchi A, Protzel C, Watkin N, Compérat E. EAU Guidelines on Penile Cancer 2020; 2020. Available from: http: //uroweb.org/guideline/penile-cancer/LK-Penile CancerUroweb%7CFG-0.
Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer. 2013; 109(10): 2554-9.
Cocks M, Taheri D, Ball MW, Bezerra SM, Del Carmen Rodriguez M, Ricardo BFP, et al. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Hum Pathol. 2017; 59: 55-61.
Ali SM, Pal SK, Wang K, Palma NA, Sanford E, Bailey M, et al. Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations. Oncologist. 2016; 21(1): 33-9.
Trafalis DT, Alifieris CE, Kalantzis A, Verigos KE, Vergadis C, Sauvage S. Evidence for efficacy of treatment with the Anti-PD-1 Mab nivolumab in radiation and multichemorefractory advanced penile squamous cell carcinoma. J Immunother. 2018; 41(6): 300-5.
Chahoud J, Skelton WP, Spiess PE, Walko C, Dhillon J, Gage KL, et al. Case report: two cases of chemotherapy refractory metastatic penile squamous cell carcinoma with extreme durable response to Pembrolizumab. Front Oncol. 2020; 10: 1-6.
Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R, et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer. 2020; 138: 125-32.
Baweja A, Mar N. Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab. J Oncol Pharm Pract. 2021; 27(1): 212-5.
